IRadimed Corp
NASDAQ:IRMD
Intrinsic Value
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. [ Read More ]
The intrinsic value of one IRMD stock under the Base Case scenario is 28.32 USD. Compared to the current market price of 40.36 USD, IRadimed Corp is Overvalued by 30%.
Valuation Backtest
IRadimed Corp
Run backtest to discover the historical profit from buying and selling IRMD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
IRadimed Corp
Current Assets | 71.9m |
Cash & Short-Term Investments | 46.8m |
Receivables | 12.8m |
Other Current Assets | 12.4m |
Non-Current Assets | 15.5m |
PP&E | 11m |
Intangibles | 2.5m |
Other Non-Current Assets | 2m |
Current Liabilities | 7.9m |
Accounts Payable | 2.8m |
Accrued Liabilities | 2.8m |
Other Current Liabilities | 2.3m |
Non-Current Liabilities | 5m |
Other Non-Current Liabilities | 5m |
Earnings Waterfall
IRadimed Corp
Revenue
|
65.6m
USD
|
Cost of Revenue
|
-15.4m
USD
|
Gross Profit
|
50.2m
USD
|
Operating Expenses
|
-30.1m
USD
|
Operating Income
|
20m
USD
|
Other Expenses
|
-2.8m
USD
|
Net Income
|
17.2m
USD
|
Free Cash Flow Analysis
IRadimed Corp
What is Free Cash Flow?
IRMD Profitability Score
Profitability Due Diligence
IRadimed Corp's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
IRadimed Corp's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
IRMD Solvency Score
Solvency Due Diligence
IRadimed Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
IRadimed Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IRMD Price Targets Summary
IRadimed Corp
According to Wall Street analysts, the average 1-year price target for IRMD is 60.18 USD with a low forecast of 56.56 USD and a high forecast of 64.05 USD.
Ownership
IRMD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IRMD Price
IRadimed Corp
Average Annual Return | 14.06% |
Standard Deviation of Annual Returns | 66.5% |
Max Drawdown | -49% |
Market Capitalization | 508.5m USD |
Shares Outstanding | 12 739 100 |
Percentage of Shares Shorted | 1.48% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.
Contact
IPO
Employees
Officers
The intrinsic value of one IRMD stock under the Base Case scenario is 28.32 USD.
Compared to the current market price of 40.36 USD, IRadimed Corp is Overvalued by 30%.